Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
about
Drug Points: pancreatitis associated with hydroxyurea in combination with didanosineIn vitro hydroxyurea decreases Th1 cell-mediated immunityInfluence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review.Hydroxyurea to inhibit human immunodeficiency virus-1 replication.Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rateImmunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDSVS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.In vitro reactivation of latent HIV-1 by cytostatic bis(thiosemicarbazonate) gold(III) complexesUpdate on didanosine.Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.Curing HIV: lessons from cancer therapyNovel inhibitors of human immunodeficiency virus type 2 infectivity.Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequenciesMelanonychia and mucocutaneous hyperpigmentation due to hydroxyurea use in an HIV-infected patient.Anti-human immunodeficiency virus drug combination strategies.
P2860
Q28345765-F85473ED-5628-449E-8E85-FFB74C6E7FD4Q28367791-83877F01-FF94-441A-9435-39537286ADE6Q30453160-6A34B13F-1C51-4D96-9B05-203DDD84B032Q33418406-524B804B-9EDB-4318-842C-E2C601A4B26EQ33536010-449E549B-1CA0-49AD-B714-749C0E7ACAB9Q33784748-9EB3120D-16CF-40F7-84AB-4EF51BF2706EQ34255648-B477FE0F-B791-4255-A269-DD2B17C65358Q34356110-1966D0EE-79E8-40BC-AB3A-7384F2E1DB22Q34456352-C19359A8-D85A-4DB9-ADAC-E6EF1D7C7B4EQ34694631-1E33918C-9421-4A46-A632-81A575722B25Q35207285-3785CCAE-A38C-4A89-B631-02CDE7CAFDD9Q36240086-425DC53D-D81D-4D71-AB31-2F4D75B462E1Q37851515-418C4FC1-25F5-448A-BC93-EE34543490ADQ38085989-29E4DE99-A183-44AE-B856-4FE230C065E3Q38967949-7318334F-F34B-4D8E-BC20-584BECDFE776Q39471555-389CA818-787F-4685-BC72-FA28349298EAQ39603104-6B65BDCC-8E24-4144-9256-41295C4D8BEDQ39684476-77592C73-E8FA-4F36-A6B6-E9CD5C0D6908Q44879165-D4F21531-D8B6-4F5B-B7B9-96DB23FD27ADQ45752028-A4E343C9-89F6-4D0E-935F-D42F22B9BC1F
P2860
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Combination of a drug targetin ...... iency virus type 1 resistance.
@en
Combination of a drug targetin ...... iency virus type 1 resistance.
@nl
type
label
Combination of a drug targetin ...... iency virus type 1 resistance.
@en
Combination of a drug targetin ...... iency virus type 1 resistance.
@nl
prefLabel
Combination of a drug targetin ...... iency virus type 1 resistance.
@en
Combination of a drug targetin ...... iency virus type 1 resistance.
@nl
P2093
P356
P1476
Combination of a drug targetin ...... iency virus type 1 resistance.
@en
P2093
De Antoni A
Degli Antoni A
Lisziewicz J
Maserati R
P304
P356
10.1089/AID.1997.13.1403
P50
P577
1997-11-01T00:00:00Z